低剂量艾美赛珠单抗预防治疗重型血友病A患者:一项为患者带来新希望的回顾性研究
本回顾性研究通过病历回顾比较低剂量艾美赛珠单抗(每月3 mg/kg,无负荷剂量,n=10)与低剂量凝血因子VIII预防治疗(每次10-20 IU/kg,每周两次,n=10)的疗效与安全性。结果显示低剂量艾美赛珠单抗组所有结局指标均显著优于低剂量凝血因子VIII组,直接费用约6000美元,与低剂量重组凝血因子VIII的6282美元相近,远低于标准剂量艾美赛珠单抗的约15000美元。作者认为低剂量艾美赛珠单抗提供了成本有效的治疗选择,可改善发展中国家的可及性,但需在更大规模及更好对照的研究中确认。
要点
- 低剂量艾美赛珠单抗组所有结局指标均显著优于低剂量凝血因子VIII预防治疗组。
- 低剂量艾美赛珠单抗治疗后6个月旋转血栓弹力法凝血时间中位数与轻型血友病患者相当。
- 低剂量艾美赛珠单抗直接费用约6000美元,低于标准剂量艾美赛珠单抗的约15000美元。
核心结论
- 低剂量艾美赛珠单抗提供了成本有效的治疗选择,可改善发展中国家的可及性。
- 这些发现需在更大规模及更好对照的研究中确认。
研究设计与样本
- 回顾性病历审查研究,经伦理批准后比较两组患者。
- 第1组为低剂量艾美赛珠单抗(n=10;每月3 mg/kg,无负荷剂量)。
- 第2组为低剂量凝血因子VIII预防治疗(n=10;每次10-20 IU/kg,每周两次)。
主要发现
- 低剂量艾美赛珠单抗组所有结局指标均显著优于低剂量凝血因子VIII预防治疗组。
- 非活化旋转血栓弹力法凝血时间在低剂量艾美赛珠单抗组治疗6个月后的中位数与轻型血友病患者相当,而低剂量凝血因子VIII组与中型血友病患者相似。
- 低剂量艾美赛珠单抗的直接费用约为6000美元。
- 本研究中低剂量重组凝血因子VIII预防治疗的费用为6282美元(根据因子类型可能在3432至7920美元之间)。
- 标准剂量艾美赛珠单抗的费用约为15000美元。
关键数值与推荐
- 结局指标包括靶关节、年出血率、年关节出血率、血友病关节健康评分、非活化旋转血栓弹力法凝血时间、血浆艾美赛珠单抗水平及直接治疗费用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现需在更大规模及更好对照的研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose emicizumab can potentially offer a cost-effective treatment option in persons with hemophilia A, especially in developing countries. OBJECTIVES: To compare the efficacy and safety of low-dose emicizumab with those on low-dose factor (F)VIII prophylaxis via chart review. METHODS: After ethics approval, chart data of 2 groups of patients were reviewed: group 1 (low-dose emicizumab, n = 10; 3 mg/kg monthly without a loading dose) and group 2 (low-dose FVIII prophylaxis, n = 10; 10-20 IU/kg of FVIII concentrates twice a week). Outcomes were target joints, annual bleeding rate, annual joint bleeding rate, Hemophilia Joint Health Score, nonactivated thromboelastometry-rotational thromboelastometry clotting time, plasma emicizumab levels, and direct costs of treatment. RESULTS: All outcome measures were significantly better in the low-dose emicizumab group than in the low-dose FVIII prophylaxis group. For nonactivated thromboelastometry-rotational thromboelastometry, median values after 6 months in the low-dose emicizumab group were comparable with values seen in patients with mild hemophilia, while the values in the low-dose FVIII prophylaxis group were similar to those of patients with moderate hemophilia. The direct cost of low-dose emicizumab was found to be approximately US $6000 and that for low-dose recombinant FVIII prophylaxis used in our study was US $6282 (the cost may range from US $3432 to $7920 depending on the type of factor) when compared to approximately US $15 000 for standard-dose emicizumab. CONCLUSION: Low-dose emicizumab offers a cost-effective treatment option and can improve access in developing countries. These findings need to be confirmed in a larger and better-controlled study.
引用
- Patil R, Shanmukhaiah C, Gogtay NJ, et al. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients. J Thromb Haemost. 2023. PMID: 38160726. doi:10.1016/j.jtha.2023.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。